Annual cost of hospitalization, inpatient rehabilitation and sick leave of anal cancer in Germany
Authors:
- 14 December 2012
- journal article
- Published by Informa Healthcare in Journal of Medical Economics
- Vol. 16 (3) , 364-371
Abstract
Objective: Literature on the economic burden of anal cancer in Germany is scarce. About 84% of these cancers are associated with human papillomavirus infection. This study, therefore, aimed to assess the annual costs of human papillomavirus-related anal cancer incurred by hospitalization, inpatient rehabilitation, and sick leave in 2008 in Germany. Methods: A cross-sectional retrospective analysis of five German databases covering hospital treatment, inpatient rehabilitation, and sick leave in 2008 was performed. All hospital, inpatient rehabilitation, and sick leave cases due to anal cancer in 2008 were analyzed. Associated numbers of anal cancer hospitalizations, healthcare resource use, and costs were identified and extracted using the ICD-10 code C21 as the main diagnosis. The annual cost of human papillomavirus-related anal cancer was estimated based on the percentage of anal cancer likely to be attributable to human papillomavirus. Results: In 2008, there were 5774 hospitalizations (39% males, 61% females), 517 inpatient rehabilitations, and 897 sick leaves due to anal cancer representing costs of €34.11 million. The estimated annual costs associated with human papillomavirus-related anal cancer were €28.72 million, mainly attributed to females (62%). Direct costs accounted for 90% (86% for hospital treatment, 4% for inpatient rehabilitation) and indirect costs due to sick leave accounted for 10% of human papillomavirus-related costs. Conclusions: The economic burden of human papillomavirus-related anal cancer in 2008 in Germany is under-estimated, since costs incurred by outpatient management, outpatient chemotherapy, long-term care, premature retirement, and premature death were not included. However, this study is the first analysis to investigate the economic burden of anal cancer in Germany. The estimated annual costs of human papillomavirus-related anal cancer contribute to a significant economic burden in Germany and should be considered when assessing health and economic benefits of human papillomavirus vaccination in both genders.Keywords
This publication has 12 references indexed in Scilit:
- Economic burden of anal cancer management in FranceRevue D'Épidémiologie Et de Santé Publique, 2010
- Cancer management and reimbursement aspects in Germany: an overview demonstrated by the case of colorectal cancerThe European Journal of Health Economics, 2009
- Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: A meta‐analysisInternational Journal of Cancer, 2009
- Years of potential life lost and productivity costs because of cancer mortality and for specific cancer sites where human papillomavirus may be a risk factor for carcinogenesis-United States, 2003Cancer, 2008
- German Recommendations on Health Economic Evaluation: Third and Updated Version of the Hanover ConsensusValue in Health, 2008
- The economic burden of noncervical human papillomavirus disease in the United StatesAmerican Journal of Obstetrics and Gynecology, 2008
- Anal Cancer: An OverviewThe Oncologist, 2007
- Chapter 2: The burden of HPV-related cancersVaccine, 2006
- Anal intraepithelial neoplasiaBritish Journal of Surgery, 2005
- Human papillomavirus, smoking, and sexual practices in the etiology of anal cancerCancer, 2004